Literature DB >> 19292802

Locoregional relapse after breast cancer: most relapses occur late and are not clinically detected.

David A Montgomery1, Katherine Krupa, Timothy G Cooke.   

Abstract

There remains controversy over follow-up after breast cancer. The National Institute for Clinical Excellence (NICE) in the United Kingdom recommends 2-3 years of follow-up for the detection of locoregional relapse. Guidelines in North America advocate much longer follow up periods. Clinicians in the UK have been reluctant to implement the NICE guidelines. Previous studies report that the rate of relapse peaks in the first 3-5 years before falling off. In this study, a retrospective analysis of rate of relapse and method of detection in 198 patients treated with conservation surgery between 1995 and 2001 has been undertaken. Median follow-up was 5.9 years. Rate of relapse is essentially constant for 10 years, with most relapses occurring after 3 years. The majority of relapse in this cohort is detected by means other than routine clinical examination, with only 16.66% of relapse detected this way. The guidelines for follow-up in the UK need revision. If follow-up is to be provided, this needs to continue for at least 10 years, if not beyond. This study casts doubt on the value of routine clinical examination.

Entities:  

Mesh:

Year:  2009        PMID: 19292802     DOI: 10.1111/j.1524-4741.2009.00691.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  7 in total

1.  Utility of Clinical Breast Examinations in Detecting Local-Regional Breast Events After Breast-Conservation in Women with a Personal History of High-Risk Breast Cancer.

Authors:  Heather B Neuman; Jessica R Schumacher; Amanda B Francescatti; Taiwo Adesoye; Stephen B Edge; Elizabeth S Burnside; David J Vanness; Menggang Yu; Yajuan Si; Dan McKellar; David P Winchester; Caprice C Greenberg
Journal:  Ann Surg Oncol       Date:  2016-08-04       Impact factor: 5.344

2.  Stanniocalcin Expression as a Predictor of Late Breast Cancer Recurrence.

Authors:  Kristen D Brantley; Anders Kjærsgaard; Deirdre Cronin-Fenton; Rami Yacoub; Anja S Nielsen; Kristina L Lauridsen; Stephen Hamilton-Dutoit; Timothy L Lash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-28       Impact factor: 4.254

3.  Long-term follow-up of women with breast cancer: rationale for policy change.

Authors:  T McCarthy; L Mullen; H Murphy; D Carey; M Laffoy
Journal:  Ir J Med Sci       Date:  2014-10-01       Impact factor: 1.568

4.  Options for early breast cancer follow-up in primary and secondary care - a systematic review.

Authors:  Frances Taggart; Peter Donnelly; Janet Dunn
Journal:  BMC Cancer       Date:  2012-06-13       Impact factor: 4.430

5.  Open access follow-up care for early breast cancer: a randomised controlled quality of life analysis.

Authors:  M N Kirshbaum; J Dent; J Stephenson; A E Topping; V Allinson; M McCoy; S Brayford
Journal:  Eur J Cancer Care (Engl)       Date:  2016-09-26       Impact factor: 2.520

6.  Recommendations for breast imaging follow-up of women with a previous history of breast cancer: position paper from the Italian Group for Mammography Screening (GISMa) and the Italian College of Breast Radiologists (ICBR) by SIRM.

Authors:  Lauro Bucchi; Paolo Belli; Eva Benelli; Daniela Bernardi; Beniamino Brancato; Massimo Calabrese; Luca A Carbonaro; Francesca Caumo; Beatrice Cavallo-Marincola; Paola Clauser; Chiara Fedato; Alfonso Frigerio; Vania Galli; Livia Giordano; Paola Golinelli; Giovanna Mariscotti; Laura Martincich; Stefania Montemezzi; Doralba Morrone; Carlo Naldoni; Adriana Paduos; Pietro Panizza; Federica Pediconi; Fiammetta Querci; Antonio Rizzo; Gianni Saguatti; Alberto Tagliafico; Rubina M Trimboli; Chiara Zuiani; Francesco Sardanelli
Journal:  Radiol Med       Date:  2016-09-06       Impact factor: 3.469

7.  Developing an aftercare decision aid; assessing health professionals' and patients' preferences.

Authors:  Linda Klaassen; Carmen Dirksen; Liesbeth Boersma; Ciska Hoving
Journal:  Eur J Cancer Care (Engl)       Date:  2017-07-20       Impact factor: 2.520

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.